Don’t miss out on the next big thing in the life sciences.

Podcast: Surviving and Thriving in the Long Biotech Winter

The IPO market remains unwelcoming to biotechs and venture investors are reticent to back younger companies. In the absence of reliable funding sources, many biotechs are trying to advance their most promising programs while keeping their operations lean until they can get to a fundable milestone. We spoke to Kevin Sarney, Life Sciences Practice Leader for Charles River CFO, about the current uncertainty biotechs face, the need for capital efficiency, and how companies can best prepare for future opportunities.